Oncoustics AI
Ignacio Oyarzabal is a software developer at Oncoustics since October 2022, specializing in signal processing and ultrasound quantification. Prior experience includes a role at DeustoTech - Instituto Tecnológico Deusto from July 2021 to August 2022, focused on research and development of machine learning systems for liver disease detection. Ignacio also completed an MBA internship at IMEGUISA in April 2022 and worked in R&D for KPMG's Corporate Tax Services from January to July 2021, concentrating on innovation financing and project design. Earlier, Ignacio developed data extraction methods at IMEGUISA in 2019 to monitor production orders in real-time. Academically, Ignacio is pursuing a PhD in Engineering for the Information Society and Sustainable Development at the University of Deusto, and holds an MBA from Universidad Internacional de La Rioja and a bachelor's degree in Computer Engineering from the University of Deusto.
This person is not in any offices
Oncoustics AI
Oncoustics is creating and deploying advanced AI solutions for low cost, non-invasive surveillance, diagnostics, and treatment monitoring of diseases with high unmet clinical need. Unlike other players in the space, Oncoustics does not do image recognition. Instead, Oncoustics applies AI to raw ultrasound signals from readily available handheldultrasound devices to rapidly differentiate healthy versus diseased tissues. There's a wealth of information in these raw signals and this approach reveals novel biomarkers that can be aligned with existing standards and categorization systems. Initially targeting liver disease, a $30B global diagnostic market, Oncoustics has filed a Breakthrough Device Designation Request with the FDA for the OnX that detects liver fibrosis and the 510K is underway. Several follow-on liver products are in development. Oncoustics also has clinical data on other organ indications including prostate, kidney, breast and thyroid diseases and cancers.